Recent research explored opportunities to improve care for those with acute migraine.
What percentage of adults with acute migraine pain are eligible for new or emerging treatments?
A recent abstract presented at a recent migraine meeting sought to estimate that figure in order to get a clearer picture of unmet needs.
Researchers noted that an American Headache Society (AHS) Consensus Statement released last year indicates that novel medications for acute migraine treatment are to be considered in “patients who have contraindications to the use of triptans or who have failed to respond to or tolerate at least 2 oral triptans.”
That may have stemmed from economic concerns, said the researchers, but getting care earlier may be beneficial by reducing the risk of chronic migraine.
The researchers, who sought to understand the impact of loosening the recommendation from 2 triptans to 1, surveyed US patients in 2018 via a web-based survey of 21,143 people with migraine. People with ≥4 migraine headache days(M HDs)/month were oversampled. The survey included the migraine Treatment Optimization Questionnaire (mTOQ), which measures the adequacy of treatment for current acute therapy. A score of less than 6 on the mTOC indicates poor or very poor treatment efficacy.
A population size of those potentially eligible for novel medications was created by forming 3 groups and looking at their medication use and healthcare visits:
The mean age of the sample was 42 and most were female (74%). In total, 12,299 (58.2%) people with migraine reported 0-3 MHDs/month; 8844 (41.8%) reported ≥4 MHDs/month.
Regarding healthcare utilization in the past year, 57.7% (0-3 MHDs) and 75% (≥4 MHDs) of eligible people sought migraine care; 23% and 30.3% sought emergency department (ED) care.
Oral triptan use among those with ≥4 MHDs (39.3%) was higher; patients in this category also used more opioids and barbiturates.
Combining the 3 groups, 2594 (21.1%) people with 0-3 MHDs and 2448 (27.7%) with ≥4 MHDs are eligible for novel medications, the researchers wrote. Based on the oversampling results, about 24% of patients are eligible for novel medications, they reported.
While loosening the recommendation from 2 failed triptans to 1 increases the eligible population by a little more than 11%, it may save on care delays, the researchers said. It may also reduce inappropriate care and reduce ED visits.
Reference
Pohl G, Lipton R, Araujo A, et al. Who is eligible for novel medications designed for acute treatment of migraine and what are their unmet needs? Results of Overcome study. Presented at: Migraine Trust International Symposium; October 3-9, 2020. Abstract MTV20-DP-041.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More